Column

Most Recent

Poisoning the Poison

By | October 1, 2007

A new biologic could save the thousands of people killed by pesticides every year.

3 Comments

What is Your Brain Worth?

By | October 1, 2007

Neurological diseases cost billions, but we shouldn't overspend on brain research.

8 Comments

Me First!

By | September 1, 2007

The system of scientific authorship is in crisis. Two new rules could help make things right.

5 Comments

Out of Africa

By | September 1, 2007

A once-obscure virus spreads its wings, sickening hundreds. How did this happen?

1 Comment

Goodbye to Oranges?

By | August 1, 2007

A virus has the orange industry in trouble, and growers are partly to blame.

3 Comments

How Much Should Gardasil Cost?

By | August 1, 2007

Merck could cut the price of its new vaccine by 90% and still do very well.

4 Comments

Do Universities Need Quotas?

By | July 1, 2007

Many groups are underrepresented at schools, and Brazil's trying to do something about it.

0 Comments

Thanks, Andrew Speaker

By | July 1, 2007

One man with TB shows the world why the quarantine system often doesn't work.

2 Comments

No More Periods - Period

By | June 1, 2007

Human nature and the end of menstruation.

8 Comments

Programmed Dissatisfaction

By | June 1, 2007

Does one gene drive all progress in science and the arts?

0 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham